Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous ...
C-레벨 임원은 회사의 재무 전략과 혁신을 이끄는 응집된 리더십 팀입니다.
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
| Marc A. Stapley | Chief Executive Officer & Director | USD 1,531,000 | 1970 | Active | |
| Phillip G. Febbo | Chief Scientific & Medical Officer | USD 930,089 | — | 1966 | Active |
| Rebecca Chambers | Executive Vice President & Chief Financial Officer | USD 911,950 | 1978 | Active | |
| John Leite | Global Chief Commercial Officer | USD 846,485 | — | 1972 | Active |
| Annie McGuire | Executive VP, General Counsel & Head of Market Access | USD 829,500 | 1980 | Active | |
| Keith Gligorich | Senior Vice President of Global Operations | — | — | — | Active |
| Jonathan Wygant | Vice President & Chief Accounting Officer | — | 1971 | Active | |
| Karen Possemato | Senior Vice President of Corporate Marketing, Communications & Commercial Operations | — | — | Active | |
| Steven French | Senior Vice President & Chief Information Officer | — | — | Active | |
| Kevin Richard Haas | Chief Development and Technology Officer | — | — | 1985 | Active |
| Kelly Gura | Director of Investor Relations | — | — | Active | |
| Tracy Ward | Chief Human Resources Officer | — | — | Active |
| Filing Date | Year | Name | Position | Level | Salary | Bonus | Stock Award | Option Award | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-22 | 2025 | Marc Stapley | Chief Chief Executive Officer | Founder / CEO | $700.00K | $0 | $5.89M | $0 | $826.00K | $5.00K | $7.42M |
| 2026-04-22 | 2025 | John Leite Global | Chief Chief Commercial Officer | C-Level | $510.30K | $0 | $2.36M | $0 | $331.19K | $5.00K | $3.20M |
| 2026-04-22 | 2025 | Rebecca Chambers | Chief Chief Financial Officer | C-Level | $550.00K | $0 | $1.96M | $0 | $356.95K | $5.00K | $2.88M |
| 2026-04-22 | 2025 | Annie McGuire | General General Counsel and Head of Market Access | Other | $500.00K | $0 | $1.96M | $0 | $324.50K | $5.00K | $2.79M |
| 2026-04-22 | 2025 | Phillip Febbo | Chief Chief Scientific Officer and Chief Chief Medical Officer | C-Level | $561.00K | $0 | $1.57M | $0 | $364.09K | $5.00K | $2.50M |
| 2026-04-22 | 2024 | Marc Stapley | Chief Chief Executive Officer | Founder / CEO | $675.00K | $0 | $5.13M | $0 | $1.01M | $3.00K | $6.82M |
| 2026-04-22 | 2024 | Rebecca Chambers | Chief Chief Financial Officer | C-Level | $530.40K | $0 | $2.67M | $0 | $437.58K | $3.00K | $3.65M |
| 2026-04-22 | 2024 | John Leite Global | Chief Chief Commercial Officer | C-Level | $472.50K | $0 | $2.23M | $0 | $389.81K | $3.00K | $3.09M |
| 2026-04-22 | 2024 | Annie McGuire | General General Counsel and Head of Market Access | Other | $470.80K | $0 | $2.23M | $0 | $388.41K | $3.00K | $3.09M |
| 2026-04-22 | 2024 | Phillip Febbo | Chief Chief Scientific Officer and Chief Chief Medical Officer | C-Level | $550.00K | $0 | $1.78M | $0 | $453.75K | $3.00K | $2.79M |
| 2026-04-22 | 2023 | Marc Stapley | Chief Chief Executive Officer | Founder / CEO | $650.00K | $0 | $3.70M | $1.93M | $900.25K | $3.00K | $7.18M |
| 2026-04-22 | 2023 | Phillip Febbo | Chief Chief Scientific Officer and Chief Chief Medical Officer | C-Level | $137.50K | $0 | $2.34M | $1.21M | $104.74K | $3.00K | $3.79M |
| 2026-04-22 | 2023 | Rebecca Chambers | Chief Chief Financial Officer | C-Level | $510.00K | $0 | $1.23M | $642.47K | $388.49K | $3.00K | $2.78M |
| 2026-04-22 | 2023 | Annie McGuire | General General Counsel and Head of Market Access | Other | $440.00K | $0 | $1.11M | $578.21K | $335.17K | $16.55K | $2.48M |
| 2026-04-22 | 2023 | John Leite Global | Chief Chief Commercial Officer | C-Level | $421.07K | $0 | $858.05K | $377.92K | $264.43K | $3.00K | $1.92M |
Sum of disclosed compensation by year (USD million)
Top founder/C-level executives over time (USD million)
